Evidence map›Paper›PMID 30568606›Full record

ReviewFrontiers in psychiatry2018

Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia.

Nicole E MacKenzie, Chantel Kowalchuk, Sri Mahavir Agarwal, Kenya A Costa-Dookhan, Fernando Caravaggio, Philip Gerretsen, Araba Chintoh, Gary J Remington, Valerie H Taylor, Daniel J Müeller and 2 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in psychiatry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 119 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
119citing papers in PubMed, 2 pooled it
11.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

119 citing papers in PubMed, 2 syntheses or guidelines pooled it, 204 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

59 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Nicole E MacKenzieCentre for Addiction and Mental Health, Toronto, ON, Canada.
Chantel KowalchukCentre for Addiction and Mental Health, Toronto, ON, Canada.
Sri Mahavir AgarwalCentre for Addiction and Mental Health, Toronto, ON, Canada.
Kenya A Costa-DookhanCentre for Addiction and Mental Health, Toronto, ON, Canada.
Fernando CaravaggioCentre for Addiction and Mental Health, Toronto, ON, Canada.
Philip GerretsenCentre for Addiction and Mental Health, Toronto, ON, Canada.
Araba ChintohCentre for Addiction and Mental Health, Toronto, ON, Canada.
Gary J RemingtonCentre for Addiction and Mental Health, Toronto, ON, Canada.
Valerie H TaylorDepartment of Psychiatry, University of Toronto, Toronto, ON, Canada.
Daniel J MüellerCentre for Addiction and Mental Health, Toronto, ON, Canada.
Ariel Graff-GuerreroCentre for Addiction and Mental Health, Toronto, ON, Canada.
Margaret K HahnCentre for Addiction and Mental Health, Toronto, ON, Canada.
Centre for Addiction and Mental Health · CAUniversity of Toronto · CA

Funding

Mitochondrial Dysfunction In SchizophreniaR01MH085801 · NIMH · UNIVERSITY OF CALIFORNIA-IRVINE · PI VAWTER, MARQUIS PHILIP · 2009 to 2020
$5.0M
NIMH NIH HHS R01 MH085801
6 · The paper itself

Abstract

Cognitive impairment is a core symptom domain of schizophrenia. The effect of antipsychotics, the cornerstone of treatment in schizophrenia, on this domain is not fully clear. There is some evidence suggesting that antipsychotics may partially improve cognitive function, and that this improvement may vary depending on the specific cognitive domain. However, this research is confounded by various factors, such as age, duration/stage of illness, medication adherence, and extrapyramidal side effects that complicate the relationship between antipsychotics and cognitive improvement. Furthermore, antipsychotics-particularly the second generation, or "atypical" antipsychotics-can induce serious metabolic side effects, such as obesity, dyslipidemia and type 2 diabetes, illnesses which themselves have been linked to impairments in cognition. Thus, the inter-relationships between cognition and metabolic side effects are complex, and this review aims to examine them in the context of schizophrenia and antipsychotic treatment. The review also speculates on potential mechanisms underlying cognitive functioning and metabolic risk in schizophrenia. We conclude that the available literature examining the inter-section of antipsychotics, cognition, and metabolic effects in schizophrenia is sparse, but suggests a relationship between metabolic comorbidity and worse cognitive function in patients with schizophrenia. Further research is required to determine if there is a causal connection between the well-recognized metabolic adverse effects of antipsychotics and cognitive deficits over the course of the illness of schizophrenia, as well as, to determine underlying mechanisms. In addition, findings from this review highlight the importance of monitoring metabolic disturbances in parallel with cognition, as well as, the importance of interventions to minimize metabolic abnormalities for both physical and cognitive health.

Indexed as

antipsychoticscognitive dysfunctioninter-relationshipmechanismmetabolic syndromeschizophrenia

Identifiers

PMID30568606
PMCPMC6290646
OpenAlexW2902303283

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.